Drugs and Devices

FDA approves maintenance treatment for patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer

On March 27, the U.S. Food and Drug Administration (FDA) approved Zejula (niraparib) for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, whose tumors responded completely or partially to platinum-based chemotherapy. Read more


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Newsletter Subscribe

  • This field is for validation purposes and should be left unchanged.

Test Your Nursing Knowledge

Answer this interactive quiz to be entered to win a gift card.

  • This field is for validation purposes and should be left unchanged.

Insights Blog

Today’s News in Nursing

Shares